Damora Therapeutics (DMRA)
Advances mutCALR-directed candidates for essential thrombocythemia and myelofibrosis.
$28.22
At close+0.08 (+0.28%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions64 holders · as of Mar 31, 2026 | 90.97% | 56.00M shares | |
| Insiders2 holders · as of Jul 7, 2026 | 0.82% | 502.3K shares | |
| Otherremainder | 8.21% | 5.05M shares |
61.55M company shares as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Institutions13F, as of Mar 31, 2026
64 holders · 56.00M shares · 50 new positions · 63 increased · 0 reduced · 4 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 9.05M | 14.70% | +8.81M | May 15, 2026 |
| Fairmount Funds Management LLC | 8.71M | 14.16% | +8.71Mnew | May 15, 2026 |
| Avoro Capital Advisors LLC | 3.78M | 6.15% | +3.78Mnew | May 15, 2026 |
| VR Adviser, LLC | 3.60M | 5.85% | +3.60Mnew | May 15, 2026 |
| FCPM Iii Services B.V. | 2.44M | 3.97% | +2.44Mnew | May 15, 2026 |
| Ra Capital Management, L.P. | 2.40M | 3.90% | +2.40Mnew | May 15, 2026 |
| Janus Henderson Group PLC | 2.36M | 3.84% | +2.36M | May 18, 2026 |
| Viking Global Investors LP | 2.31M | 3.75% | +2.31Mnew | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jul 6, 2026 | Garrett Winslowofficer: General Counsel | Sale | 245 | $29.98 | 2,289 |
CongressHouse and Senate disclosures
Not reported.